Cure8 research brief
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require intensification of advanced treatments and may guide clinician–patient planning.
Clinicians treating IBD; researchers of real-world treatment patterns; adult patients with Crohn’s disease or ulcerative colitis interested in treatment optimization
This Scientific Reports analysis used Brazil’s GEDIIB national IBD registry (June 2023–June 2024) to identify clinical features linked with “advanced therapy optimization” (use and dose/strategy changes of biologic or small-molecule therapies) in Crohn’s disease (CD) and ulcerative colitis (UC).
The authors report higher use and more frequent optimization of advanced therapies in CD than UC and describe patient-level factors associated with optimization in each disease.
In Crohn’s disease, younger age at onset (A1 and A2), presence of perianal disease, and prior abdominal surgery involving an ileal pouch were independently associated with greater prevalence of optimization.
In ulcerative colitis, prior surgery, chronic liver disease, and prior herpes zoster infection were associated with higher prevalence of optimization on multivariable analysis. These findings are registry-based and observational: they describe associations rather than proving causation.
The study may help clinicians and patients understand which subgroups more often require intensified advanced-treatment strategies and could inform discussions about monitoring and treatment planning.
Registry-based, retrospective design—associations not causation; findings may reflect local practice patterns in Brazil and registry data limitations.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Organização Brasileira de Doença de Crohn e Colite
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
